Nurix Therapeutics, Inc. (NRIX)
Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Filings
239 filings since 2017 beside 318 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Nov 30, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Jan 29, 2027
10-Q
Quarterly report for the quarter ending Feb 28, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by Apr 9, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Mar 27, 2026.
Filings a yearinsider forms included
14794666010684100
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 4 times in the last 36 months, the newest Nov 10, 2025.SEC letters: 3 in the last 36 months, the newest Mar 19, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Jun 11, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Jun 8, 2026
8-K items 1.01, 7.01, 9.01
Major agreement signed; Investor disclosure (Regulation FD) · Current report
Jun 6, 2026
Dec 9, 2025
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Dec 6, 2025
Oct 22, 2025
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
40 of 239 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.